At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Lymphoma. Non-Hodgkin. Completed, enrolled 121 participants across 46 sites in 12 countries.
Detailed Summary
The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCT
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma. Non-Hodgkin
CountriesAustralia, Belgium, Canada, France, Germany, Italy, Netherlands, Singapore, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMar 2014
Primary CompletionApr 2016
Study CompletionOct 2020
TodayJul 2026
First PostedJan 17, 2014
Enrollment StartMar 5, 2014
Primary CompletionApr 8, 2016
Study CompletionOct 8, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.5 years ago
Interventions
Nivolumabdrug